Symvivo is a clinical stage biotech company that has developed a live cell probiotic-based gene delivery platform. We have programs in the clinical and pre-clinical space in oncology, ischemic heart disease, vaccines and rare-diseases.
Alexander Graves is the founder and CEO of Symvivo Corporation. He holds an Honours in Biomedical Sciences specializing in Biochemistry (H.BmSc) from the University of Western Ontario, as well as M.B.A. from the University of British Columbia. Alexander was recognized in the Top 30 Under 30 by BC Business Magazine for his work with Symvivo, and is a graduate of the Center for Drug Research and Developments Biotechnology Executive Training Program, a nationally competitive program for Canada’s top executives in the life sciences.
Sheetal leads the preclinical therapeutic R&D program at Symvivo Corporation. Dr. Raithatha has extensive pre-clinical drug development experience is a broad range of indications. He was formerly in the Medicinal Chemistry group at viDA Therapeutics Inc as a senior scientist, where he contributed to the design and optimization of first-in-class chemical inhibitors of extracellular proteases to treat autoimmune and chronic inflammation. He trained as a post-doctoral fellow at the Centre for Drug Research and Development contributing to the translation of validation of health-related research in Canada. Dr. Raithatha was awarded his Ph.D. in Biochemistry from the University of Alberta, and subsequently conducted post-doctoral research in gene expression and cellular development at the the University of British Columbia.
Dr. Sievers brings more than 25 years experience in the biotechnology industry and academia. His expertise spans across multiple cancer indications including acute myeloid leukemia, myelodysplastic syndromes, Hodgkin and non-Hodgkin lymphoma, melanoma, and renal cell carcinoma. He is an accomplished educator, guest speaker, and strategist, with deep understanding of trial design, experimental medicine, and both early and late stages of clinical development. Dr. Sievers most recently served as Senior Vice President, Clinical Development at Seattle Genetics, where he also held several other senior clinical leadership positions over the past nine years. Notably, during his tenure at Seattle Genetics he played a key role in the development and approval of ADCETRIS®. Dr. Sievers started his industry career as Medical Director at ZymoGenetics. Prior to joining the biotechnology industry, Dr. Sievers spent over a decade at the Fred Hutchinson Cancer Research Center practicing medicine in the areas of hematology and oncology. He received his Medical and Bachelor of Arts degrees from Brown University.